XtalPi and Pfizer Expand Partnership to Enhance AI-Driven Drug Discovery Platform
Reuters
Jun 30
XtalPi and Pfizer Expand Partnership to Enhance AI-Driven Drug Discovery Platform
XtalPi Holdings Ltd., a global leader in integrating artificial intelligence and robotics for the advancement of medical and materials science, has announced an expansion of its strategic collaboration with Pfizer. This partnership aims to develop a next-generation molecular modeling platform for drug discovery. By combining advanced physics-based methods with cutting-edge AI technology, the collaboration seeks to improve accuracy, speed, and scalability in small molecule drug discovery and development. XtalPi will leverage its XFEP platform to enhance Pfizer's proprietary chemical space, empowering diverse drug design and development scenarios. The partnership is poised to deliver transformative predictive tools, accelerating the creation of groundbreaking therapies for patients worldwide.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xtalpi Holdings Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN20889) on June 30, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.